J. Cosnes, ?. Gower, C. Rousseau, P. Seksik, and A. Cortot, Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-1794, 2011.
DOI : 10.1053/j.gastro.2011.01.055

URL : https://hal.archives-ouvertes.fr/hal-00631553

V. Edward and . Loftus-jr, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterol, vol.126, issue.6, pp.1504-1517, 2004.

C. Manichanh, N. Borruel, F. Casellas, and F. Guarner, The gut microbiota in IBD, Nature Reviews Gastroenterology & Hepatology, vol.252, issue.10, pp.599-608, 2012.
DOI : 10.1038/nrgastro.2012.152

A. Aratari, C. Papi, V. Clemente, A. Moretti, R. Luchetti et al., Colectomy rate in acute severe ulcerative colitis in the infliximab era, Digestive and Liver Disease, vol.40, issue.10, pp.821-827, 2008.
DOI : 10.1016/j.dld.2008.03.014

T. Jess, C. Rungoe, and L. Peyrin-biroulet, Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies, Clinical Gastroenterology and Hepatology, vol.10, issue.6, pp.639-684, 2012.
DOI : 10.1016/j.cgh.2012.01.010

G. Rogler, Chronic ulcerative colitis and colorectal cancer, Cancer Letters, vol.345, issue.2, p.2013
DOI : 10.1016/j.canlet.2013.07.032

A. Timmer, J. Mcdonald, D. Tsoulis, and J. Macdonald, Azathioprine and 6 -mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.10, 2012.

N. Chande, J. Macdonald, and J. Mcdonald, Methotrexate for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 2007.

P. Rutgeerts, W. Sandborn, B. Feagan, W. Reinisch, A. Olson et al., Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005.
DOI : 10.1056/NEJMoa050516

W. Sandborn, A. Van, W. Reinisch, J. Colombel, D. Haens et al., Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2012.
DOI : 10.1053/j.gastro.2011.10.032

D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik et al., Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, The Lancet, vol.380, issue.9857, pp.1909-1924, 2012.
DOI : 10.1016/S0140-6736(12)61084-8

URL : https://hal.archives-ouvertes.fr/hal-00742308

D. Turner, C. Seow, G. Greenberg, A. Griffiths, M. Silverberg et al., A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.7, issue.10, pp.1081-1089, 2009.
DOI : 10.1016/j.cgh.2009.06.024

F. Hirai, T. Matsui, K. Aoyagi, N. Inoue, T. Hibi et al., VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES, Digestive Endoscopy, vol.5, issue.1, pp.39-44, 2010.
DOI : 10.1111/j.1443-1661.2009.00916.x

S. Truelove and L. Witts, Cortisone in Ulcerative Colitis, BMJ, vol.2, issue.4947, pp.1041-1049, 1955.
DOI : 10.1136/bmj.2.4947.1041

S. Lichtiger, D. Present, A. Kornbluth, I. Gelernt, J. Bauer et al., Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

J. Mendoza and M. Abreu, Biological markers in inflammatory bowel disease: Practical consideration for clinicians, Gastroent??rologie Clinique et Biologique, vol.33, pp.158-73, 2009.
DOI : 10.1016/S0399-8320(09)73151-3

H. Iskandar and M. Ciorba, Biomarkers in inflammatory bowel disease: current practices and recent advances, Translational Research, vol.159, issue.4, pp.313-338, 2012.
DOI : 10.1016/j.trsl.2012.01.001

C. Solem, E. Loftus, W. Tremaine, W. Harmsen, A. Zinsmeister et al., Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.11, issue.8, pp.707-719, 2005.
DOI : 10.1097/01.MIB.0000173271.18319.53

D. Turner, D. Mack, J. Hyams, N. Leleiko, A. Otley et al., C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis, Journal of Crohn's and Colitis, vol.5, issue.5, pp.423-432, 2011.
DOI : 10.1016/j.crohns.2011.05.003

M. Henriksen, J. Jahnsen, I. Lygren, N. Stray, J. Sauar et al., C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, vol.57, issue.11, pp.1518-1541, 2008.
DOI : 10.1136/gut.2007.146357

S. Azad, N. Sood, and A. Sood, Biological and histological parameters as predictors of relapse in ulcerative colitis: A prospective study, Saudi Journal of Gastroenterology, vol.17, issue.3, pp.194-202, 2011.
DOI : 10.4103/1319-3767.80383

M. Pepys and G. Hirschfield, C-reactive protein: a critical update, Journal of Clinical Investigation, vol.111, issue.12, pp.1805-1817, 2003.
DOI : 10.1172/JCI200318921

S. Vermeire, G. Assche, and P. Rutgeerts, Role of biomarkers in the diagnosis of inflammatory bowel disease, Expert Opinion on Medical Diagnostics, vol.91, issue.4, pp.481-489, 2007.
DOI : 10.1136/gut.2006.113431

S. Travis, D. Schnell, P. Krzeski, M. Abreu, D. Altman et al., Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity, Gastroenterology, vol.145, issue.5, pp.16-5085, 2013.
DOI : 10.1053/j.gastro.2013.07.024

G. Gay, Complications of coloscopy, Acta Endoscopica, vol.27, issue.3, pp.195-203, 2000.
DOI : 10.1007/BF03022109

T. Lüning, M. Keemers-gels, W. Barendregt, A. Tan, and C. Rosman, Colonoscopic perforations: a review of 30,366 patients, Surgical Endoscopy, vol.13, issue.6, pp.994-1001, 2007.
DOI : 10.1007/s00464-007-9251-7

D. Foell, H. Wittkowski, T. Vogl, and R. J. , S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules, Journal of Leukocyte Biology, vol.81, issue.1, pp.28-37, 2007.
DOI : 10.1189/jlb.0306170

A. Pierce, D. Legrand, and J. Mazurier, La lactoferrine??: une prot??ine multifonctionnelle, m??decine/sciences, vol.25, issue.4, pp.361-370, 2009.
DOI : 10.1051/medsci/2009254361

I. García-montoya, T. Cendón, S. Arévalo-gallegos, and Q. Rascón-cruz, Lactoferrin a multiple bioactive protein: An overview, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1820, issue.3, pp.226-262, 2012.
DOI : 10.1016/j.bbagen.2011.06.018

N. Orsi, The antimicrobial activity of lactoferrin: Current status and perspectives, BioMetals, vol.17, issue.3
DOI : 10.1023/B:BIOM.0000027691.86757.e2

V. Gupta and R. Bamezai, Human pyruvate kinase M2: A multifunctional protein, Protein Science, vol.217, issue.Part 4, pp.2031-2075, 2010.
DOI : 10.1002/pro.505

B. Wirleitner, D. Reider, S. Ebner, G. Böck, B. Widner et al., Monocyte -derived dendritic cells release neopterin, J Leukoc Biol, vol.72, issue.6, pp.1148-53, 2002.

A. Fasano, Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer, Physiological Reviews, vol.91, issue.1, pp.151-75, 2011.
DOI : 10.1152/physrev.00003.2008

A. Tripathi, K. Lammers, S. Goldblum, T. Shea-donohue, S. Netzel-arnett et al., Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proceedings of the National Academy of Sciences, vol.106, issue.39, pp.16799-804, 2009.
DOI : 10.1073/pnas.0906773106

F. Costa, M. Mumolo, M. Bellini, M. Romano, L. Ceccarelli et al., Role of faecal calprotectin as non-invasive marker of intestinal inflammation, Digestive and Liver Disease, vol.35, issue.9, pp.642-649, 2003.
DOI : 10.1016/S1590-8658(03)00381-5

J. Langhorst, S. Elsenbruch, J. Koelzer, A. Rueffer, A. Michalsen et al., Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices, The American Journal of Gastroenterology, vol.48, issue.1, 2007.
DOI : 10.1111/j.1572-0241.2007.01556.x

P. Van-rheenen, E. Van-de-vijver, and V. Fidler, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis, BMJ, vol.341, issue.jul15 1, p.3369, 2010.
DOI : 10.1136/bmj.c3369

M. Mindemark and A. Larsson, Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry, vol.45, issue.7-8, pp.7-8552, 2012.
DOI : 10.1016/j.clinbiochem.2011.10.015

G. Chung-faye, B. Hayee, S. Maestranzi, N. Donaldson, I. Forgacs et al., Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation, Inflammatory Bowel Diseases, vol.13, issue.11, pp.1374-1382, 2007.
DOI : 10.1002/ibd.20214

J. Jeffery, S. Lewis, and R. Ayling, Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders, Inflammatory Bowel Diseases, vol.15, issue.11, pp.1630-1634, 2009.
DOI : 10.1002/ibd.20946

A. Vieira, C. Fang, E. Rolim, W. Klug, F. Steinwurz et al., Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes, BMC Research Notes, vol.2, issue.1, p.221, 2009.
DOI : 10.1186/1756-0500-2-221

A. Schoepfer, C. Beglinger, A. Straumann, M. Trummler, S. Vavricka et al., Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI, The American Journal of Gastroenterology, vol.77, issue.1, pp.162-171, 2010.
DOI : 10.1038/ajg.2009.545

E. Czub, K. Herzig, A. Szaflarska-popawska, K. Kiehne, P. Socha et al., Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.49, issue.10, pp.1147-50, 2007.
DOI : 10.1097/00005176-199105000-00005

I. Cie?ko-michalska, D. Fedak, and T. Mach, Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease, Przegl Lek, vol.67, issue.12, pp.1262-1267, 2010.

S. Nancey, G. Boschetti, D. Moussata, E. Cotte, J. Peyras et al., Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases, Inflammatory Bowel Diseases, vol.19, issue.5, pp.1043-52, 2013.
DOI : 10.1097/MIB.0b013e3182807577

N. Husain, K. Tokoro, J. Popov, S. Naides, M. Kwasny et al., Neopterin Concentration as an Index of Disease Activity in Crohn???s Disease and Ulcerative Colitis, Journal of Clinical Gastroenterology, vol.47, issue.3, pp.246-51, 2013.
DOI : 10.1097/MCG.0b013e3182582cdb

J. Gisbert, F. Bermejo, J. Pérez-calle, C. Taxonera, I. Vera et al., Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflammatory Bowel Diseases, vol.15, issue.8
DOI : 10.1002/ibd.20933

J. Tibble, G. Sigthorsson, S. Bridger, M. Fagerhol, and I. Bjarnason, Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, Gastroenterology, vol.119, issue.1, pp.15-22, 2000.
DOI : 10.1053/gast.2000.8523

Á. González-galilea, Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? (1) Journal of Crohn's & colitis, pp.144-52, 2010.

F. Costa, M. Mumolo, L. Ceccarelli, M. Bellini, M. Romano et al., Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease, Gut, vol.54, issue.3, pp.364-372, 2005.
DOI : 10.1136/gut.2004.043406

R. Mao, Y. Xiao, X. Gao, B. Chen, Y. He et al., Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies, Inflammatory Bowel Diseases, vol.18, issue.10, pp.1894-1903, 2012.
DOI : 10.1002/ibd.22861

G. Ho, H. Lee, G. Brydon, T. Ting, N. Hare et al., Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis, The American Journal of Gastroenterology, vol.55, issue.3, pp.673-681, 2009.
DOI : 10.1038/ajg.2008.119

A. Hämäläinen, Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels, World Journal of Gastroenterology, vol.17, issue.47, pp.5166-71, 2011.
DOI : 10.3748/wjg.v17.i47.5166

T. Sipponen, E. Savilahti, P. Kärkkäinen, K. Kolho, H. Nuutinen et al., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn??s disease, Inflammatory Bowel Diseases, vol.14, issue.10, pp.1392-1400, 2008.
DOI : 10.1002/ibd.20490

D. Vos, O. Dewit, D. Haens, G. Baert, F. Fontaine et al., Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na??ve patients with ulcerative colitis, Journal of Crohn's and Colitis, vol.6, issue.5, pp.557-62, 2012.
DOI : 10.1016/j.crohns.2011.11.002

P. Molander, B. Mustonen, H. Haapamäki, J. Vauhkonen, M. Kolho et al., Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF?? blocking agents, Inflammatory Bowel Diseases, vol.18, issue.11, pp.2011-2018, 2012.
DOI : 10.1002/ibd.22863

D. Vos, M. Louis, E. Jahnsen, J. Vandervoort, J. Noman et al., Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy, Inflammatory Bowel Diseases, vol.19, issue.10, pp.2111-2118, 2013.
DOI : 10.1097/MIB.0b013e31829b2a37

A. Schoepfer, M. Trummler, P. Seeholzer, B. Seibold-schmid, and F. Seibold, Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies, Inflammatory Bowel Diseases, vol.14, issue.1, pp.32-41, 2008.
DOI : 10.1002/ibd.20275

B. Abraham and S. Kane, Fecal Markers: Calprotectin and Lactoferrin, Gastroenterology Clinics of North America, vol.41, issue.2, pp.483-95, 2012.
DOI : 10.1016/j.gtc.2012.01.007

J. Langhorst and J. Boone, Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases, Drugs of Today, vol.48, issue.2, pp.149-61, 2012.
DOI : 10.1358/dot.2012.48.2.1732555